Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2006

View Archived Issues

Medivir reports significant events of the fourth quarter 2005

Development and preclinical efficacy of a novel T-cell HCV vaccine (MRKAd6-NSmut)

Spectrum reviews past year's highlights

Novel antiinfective agents reported in recent patent literature

Novel antidiabetic agents patented

New compounds with possible applicability in the treatment of inflammatory disorders described

Neuromed and Merck collaborate on novel N-type calcium channel compounds

Aquavan begins pivotal phase III program

Enrollment completed in phase II study of TH-070 for BPH

Fas-targeting fusion protein to enter clinic later this year

Satraplatin and JM-118 tested for antiangiogenic activity

Imatinib's exposure independent of ABCB1, ABCG2 and CYP3A4

Cancer cell specific apoptosis evoked by novel transcriptional inhibitor

Asthma therapy efficacious in ALS

Phase III trials of intravenous iclaprim cleared to continue

Samaritan's Alzheimer's adult stem cell drug progresses through preclinical testing

PhytoMedical expands type 2 diabetes research agreement into Alzheimer's

Curis achieves preclinical milestone in hair growth program with P&G

VISER1 trial results for Viramidine in hepatitis C

PolyMedix receives SBIR grant to develop novel antibiotic drugs

Savient and FDA agree on phase III protocol SPA for Puricase

FDA approval of expanded label for Remodulin

Additional data from phase I/II study of HuMax-CD20 in rheumatoid arthritis

Nabi outlines new plans for Gram-positive program

FDA extends review period for Tysabri in MS

Promising new therapeutic target in atherosclerosis reported / News in Context

Effective prevention of trachoma recurrence with azithromycin reported / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...